Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
312,5 USD | -0,71 % | +0,75 % | +8,49 % |
Métier
- ventes de médicaments (95,5%) : médicaments destinés au traitement des cancers, des troubles métaboliques, des maladies osseuses, des insuffisances rénales, de l'hémophilie, etc. ;
- autres (4,5%) : notamment royalties.
70,3% du CA est réalisé aux Etats-Unis.
Nombre d'employés: 26 700
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8,50 % |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15,90 % |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6,51 % |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8,91 % |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35,62 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01/01/07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01/01/15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/06/23 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/10/16 |
Robert Williams
BRD | Director/Board Member | 75 | 17/10/14 |
Robert Eckert
BRD | Director/Board Member | 69 | 01/01/03 |
Ronald Sugar
BRD | Director/Board Member | 75 | 22/07/10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24/10/17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01/01/12 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30/07/21 |
Greg Garland
BRD | Director/Board Member | 66 | 16/10/13 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 536 434 692 | 535 107 021 ( 99,75 %) | 0 | 99,75 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
BEIGENE, LTD. 19,80% | 246 269 426 | 19,80% | 2 978 709 976 $ |
NEUMORA THERAPEUTICS, INC. 22,26% | 35 368 653 | 22,26% | 320 439 996 $ |
4 910 000 | 5,50% | 105 270 400 $ | |
VIGIL NEUROSCIENCE, INC. 8,53% | 3 206 281 | 8,53% | 8 272 205 $ |
100 993 | 0,67% | 2 139 032 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Amgen Manufacturing Ltd. (Bermuda)
| |
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The company is located in Bermuda. |
Biotechnology
|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Secteur
Ventes par activité
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+8,49 % | 168 Md | |
+32,09 % | 693 Md | |
+29,39 % | 584 Md | |
-1,34 % | 372 Md | |
+20,34 % | 332 Md | |
+7,39 % | 294 Md | |
+14,25 % | 239 Md | |
-3,03 % | 211 Md | |
+10,02 % | 210 Md | |
-0,52 % | 162 Md |
- Bourse
- Actions
- Action AMGN
- Société Amgen Inc.